Abstract
Diabetic retinopathy (DR) is a major diabetes complication and the leading cause for vision loss and blindness in the adult human population. Diabetes, being an endocrinological disorder dysregulates a number of hormonal systems including the renin angiotensin system (RAS), which thereby may damage both vascular and neuronal cells in the retina. Angiotensin II (Ang II), an active component of the RAS is increased in diabetic retina, and may play a significant role in neurovascular damage leading to the progression of DR. In this review article, we highlight the role of Ang II in the pathogenesis of retinal damage in diabetes and discuss a newly identified mechanism involving tissue chymase and angiotensin-(1-12) [Ang-(1-12)] pathways. We also discuss the therapeutic effects of potential RAS inhibitors targeting blockade of cellular Ang II formation to prevent/ protect the retinal damage. Thus, a better understanding of Ang II formation pathways in the diabetic retina will elucidate early molecular mechanism of vision loss. These concepts may provide a novel strategy for preventing and/or treating diabetic retinopathy, a leading cause of blindness worldwide.
Keywords: Angiotensin II, chymase, diabetic retinopathy, neurodegeneration, oxidative stress, renin-angiotensin system, retina.
Current Medicinal Chemistry
Title:Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-( 1-12) Axis in the Pathogenesis of Diabetic Retinopathy
Volume: 24 Issue: 28
Author(s): Mohammad Shamsul Ola*, Abdullah S. Alhomida, Carlos M. Ferrario and Sarfaraz Ahmad*
Affiliation:
- Department of Biochemistry, College of Science, King Saud, University, Riyadh 11451,Saudi Arabia
- Department of General Surgery, Wake Forest University Health Science, Winston-Salem, NC 27157,United States
Keywords: Angiotensin II, chymase, diabetic retinopathy, neurodegeneration, oxidative stress, renin-angiotensin system, retina.
Abstract: Diabetic retinopathy (DR) is a major diabetes complication and the leading cause for vision loss and blindness in the adult human population. Diabetes, being an endocrinological disorder dysregulates a number of hormonal systems including the renin angiotensin system (RAS), which thereby may damage both vascular and neuronal cells in the retina. Angiotensin II (Ang II), an active component of the RAS is increased in diabetic retina, and may play a significant role in neurovascular damage leading to the progression of DR. In this review article, we highlight the role of Ang II in the pathogenesis of retinal damage in diabetes and discuss a newly identified mechanism involving tissue chymase and angiotensin-(1-12) [Ang-(1-12)] pathways. We also discuss the therapeutic effects of potential RAS inhibitors targeting blockade of cellular Ang II formation to prevent/ protect the retinal damage. Thus, a better understanding of Ang II formation pathways in the diabetic retina will elucidate early molecular mechanism of vision loss. These concepts may provide a novel strategy for preventing and/or treating diabetic retinopathy, a leading cause of blindness worldwide.
Export Options
About this article
Cite this article as:
Ola Shamsul Mohammad*, Alhomida S. Abdullah , Ferrario M. Carlos and Ahmad Sarfaraz *, Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-( 1-12) Axis in the Pathogenesis of Diabetic Retinopathy, Current Medicinal Chemistry 2017; 24 (28) . https://dx.doi.org/10.2174/0929867324666170407141955
DOI https://dx.doi.org/10.2174/0929867324666170407141955 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expression Profiles of MicroRNAs in Stem Cells Differentiation
Current Pharmaceutical Biotechnology Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes
Current Pharmaceutical Design Plasma Glucose Lowering Activity of Palmatine and its Effect on Liver, Kidney and Antioxidant Enzymes Parameters in STZ Induced Diabetic Rat Model
Current Bioactive Compounds Therapeutic Opportunities for Trophic Factors in Brain Inflammation
Current Pharmaceutical Analysis The Dynamics of the Hypothalamic-Pituitary-Ovarian Axis, ReproductivePerformance and Sexuality Following Bariatric Surgery
Current Women`s Health Reviews Dysregulation of RNA Mediated Gene Expression in Motor Neuron Diseases
CNS & Neurological Disorders - Drug Targets Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Vascular Pharmacology Isoprostanes as Biomarkers and Mediators of Oxidative Injury in Infant and Adult Central Nervous System Diseases
Current Neurovascular Research The Importance of Rhodanine Scaffold in Medicinal Chemistry: A Comprehensive Overview
Mini-Reviews in Medicinal Chemistry Diet Bioactive Compounds: Implications for Oxidative Stress and Inflammation in the Vascular System
Endocrine, Metabolic & Immune Disorders - Drug Targets A Clinical View of BDNF-TrkB Signaling in the Treatment of Major Depression
Current Signal Transduction Therapy XBP-1 and the UPRosome: Mastering Secretory Cell Function
Current Immunology Reviews (Discontinued) Circulating Nucleic Acids in Plasma and Serum: Roles in Diagnosis and Prognosis in Diabetes and Cancer
Infectious Disorders - Drug Targets Adeno-Associated Virus (AAV) Vectors in the CNS
Current Gene Therapy A New Light Device for Wound Healing
Recent Patents on Biomedical Engineering (Discontinued) Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Identification of Electrophysiological Changes in Alzheimer's Disease: A Microarray Based Transcriptomics and Molecular Pathway Analysis Study
CNS & Neurological Disorders - Drug Targets Inhibitors of Protein-Protein Interactions as Potential Drugs
Current Computer-Aided Drug Design